Walleye Capital
BCAX

Walleye Capital’s Bicara Therapeutics BCAX Stock Holding History

Walleye Capital’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.15M Buy
+108,008
New +$1.86M 0.01% 1412
2025
Q3 		– Sell
-24,308
Closed -$226K – 5263
2025
Q2 		$226K Buy
+24,308
New +$290K ﹤0.01% 3265
2024
Q4 		– Sell
-31,780
Closed -$809K – 5727
2024
Q3 		$809K Buy
+31,780
New +$810K ﹤0.01% 2854

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Walleye Capital's BCAX Position: Q1 2026 in Review

Walleye Capital opened a new position in Bicara Therapeutics (BCAX) in Q1 2026: 108,008 shares worth $2.15M. The stake represents 0.01% of the portfolio and ranks #1412 among its holdings. This is a return to the name: Walleye Capital previously reported a position in BCAX as recently as Q2 2025.

Walleye Capital first reported a position in BCAX in Q3 2024 and has held it in 3 quarters since. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Walleye Capital held 108,008 shares of Bicara Therapeutics worth $2.15M as of Q1 2026.
  • Bicara Therapeutics was a new Walleye Capital position in Q1 2026.
  • Bicara Therapeutics made up 0.01% of Walleye Capital's portfolio in Q1 2026, its #1412 holding.
  • Walleye Capital first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 3 quarters since.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.